Skip to main
CLPT

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc. has demonstrated a strong trajectory with a 17% topline growth in 2023 and a significant reduction in cash burn, highlighting improved profitability. The company is poised for at least 20% revenue growth in 2024, driven by an expanding partnership base and enhanced service offerings in the Biologics sector. Furthermore, recent key product approvals and record system installations reinforce a compelling growth narrative, positioning the firm favorably in the minimally invasive surgical device market.

Bears say

ClearPoint Neuro Inc. has demonstrated a significant reduction in cash burn, decreasing from $5.8 million in the first quarter of 2023 to $1.2 million by the fourth quarter. Despite this improvement, the ongoing dependence on cash reserves raises concerns about the company's long-term financial viability, especially given the narrow margin of cash flow relative to operational expenses. Furthermore, while there are expectations to maintain this trend into 2024, the potential for sustained growth and profitability may be limited, which could negatively impact investor confidence in the company’s future.

CLPT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLPT has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.